Jim Glasheen    GENERAL PARTNER

Jim has been with Technology Partners since 2002. Jim leads the firm's efforts in Patient-Centered Health, investing in both medical device and biopharmaceutical companies.

He serves on the boards of Elcelyx, Essentialis, and Revance Therapeutics (RVNC), while also having led Technology Partners' investment in companies that are public or have since been acquired: Iomai (IOMI - acquired by Intercell AG), Cadence Pharmaceuticals (CADX - acquired by Mallinkrodt), Incline Therapeutics (acquired by The Medicines Company), Corcept (CORT), Transcend Medical (acquired by Novartis) and Forsight Vision 5 (acquired by Allergan). Jim is also a co-founder and co-chair of ConsumerMed.org, a 501(c)(3) organization focused on patient/consumer focused healthcare.

Previously, Jim was Managing Director at CIT Venture Capital, leading the group's effort in Life Science investing. Also, Jim was a leader within McKinsey & Company's Pharmaceutical and Medical Products Practice. Jim earned a BS from Duke University and a MA and a PhD from Harvard University in biology. He was a Deutsche Akademische Austauschdienst (DAAD) fellow at Universitaet des Saarlandes, Germany and a post-doctoral fellow at University of California, Berkeley. Jim has published several research papers and had his research highlighted in major media outlets including: Nature, The New York Times, Scientific American, and CNN.

Jim can be reached at:

jim@technologypartners.com




Copyright© 2008 - 2012 Technology Partners. All rights reserved. SITE MAP